Availability (in Japan)
10 or more
(In Japan at 17:00,
Oct 8, 2024 in JST)
Size
100 µL
Data | |||||
---|---|---|---|---|---|
Clonality | Polyclonal | ||||
Isotype (Immunized Animal) | Rabbit Ig (aff.) | ||||
Applications |
|
||||
Immunogen (Antigen) | Carrier protein-conjugated Inosine | ||||
Storage buffer | PBS/50% glycerol, pH 7.2 | ||||
Storage temp. | -20°C | Conjugate | Unlabeled | Manufacturer | MBL |
Alternative names | Ino, I | ||||
Background | Adenosine-to-inosine (A-to-I) RNA editing, the most common modification that occurs in mammalian mRNAs and ncRNAs, is the conversion of adenosine to inosine catalyzed by members of the adenosine deaminase acting on RNA (ADAR) family. Because inosine has a similar chemical structure to guanosine, it pairs preferentially with cytidine. This influences the regulation of splicing, stabilization, and translation. A-to-I RNA editing also affects miRNA biogenesis and their recognition by target mRNAs. A malfunction in the editing mechanism results in various human diseases such as neurological disorders and cancers. | ||||
Related products | D347-3 Anti-Pseudouridine mAb D345-3 Anti-1-methyladenosine (m1A) mAb D346-3 Anti-5-methylcytidine (m5C) mAb PM077 Anti-5-hydroxymethylcytosine (5hmC) pAb MI-11-3 Anti-Bromodeoxyuridine mAb MI-11-5 Anti-Bromodeoxyuridine mAb-PE M218-3 Anti-5-hydroxymethylcytosine (5hmC) mAb RN019M Anti-2,2,7-trimethylguanosine (m3G/TMG) mAb RN016M Anti-7-methylguanosine (m7G)-Cap mAb RN017M Anti-7-methylguanosine (m7G) mAb |
||||
References |
|
||||
Product category |
|